Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Tumor-Agnostic 1Myeloid 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 3Sepsis 1Prostatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × 2-Propanol × Clear all
NCT04181463 2026-05-27

Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
112 enrolled
Tumor-Agnostic

Neoplasms

NCT03728335 2026-05-20

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06836271 2025-02-20

Cleaning the Biopsy Needle in TRUS Bx

Hitit University

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms, Sepsis

NCT03825796 2023-09-28

CPX-351 Plus Enasidenib for Relapsed AML

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
2 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡